Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
0.9468
-0.0490 (-4.92%)
At close: May 9, 2025, 4:00 PM
1.000
+0.053 (5.62%)
After-hours: May 9, 2025, 5:35 PM EDT
Opus Genetics Revenue
In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%. Opus Genetics had revenue of $4.30M in the quarter ending December 31, 2024, with 154.41% growth.
Revenue (ttm)
$10.99M
Revenue Growth
-42.30%
P/S Ratio
2.30
Revenue / Employee
$610,667
Employees
18
Market Cap
43.06M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IRD News
- 5 days ago - Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - GlobeNewsWire
- 6 days ago - Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision - GlobeNewsWire
- 4 weeks ago - Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns - GlobeNewsWire
- 4 weeks ago - Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases - GlobeNewsWire
- 5 weeks ago - Opus Genetics to Participate in Upcoming Investor Conference in April - GlobeNewsWire
- 5 weeks ago - Opus Genetics Announces Financial Results for Full Year 2024 - GlobeNewsWire
- 7 weeks ago - Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics - GlobeNewsWire
- 7 weeks ago - Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX - GlobeNewsWire